(6-319) Current Evidence and Future Positioning of Cereblon E3 Ligase Modulators (CELMoDs) Versus Immunomodulatory Drugs (IMiDs) in Multiple Myeloma

Tuesday, December 9, 2025

10:45 AM - 11:45 AM

Location: Bayside A, Level 1

Pharmacy School: Medical University of South Carolina College of Pharmacy
Pharmacy School Location: South Carolina

Co-Author(s): Sana Mansuri

Primary Author(s)